calcium and integrin binding family member 2Genealiases: DFNB48 · KIP2 · USH1J
Q-omics provides the consensus-scored CIB2 profile across patient tissues and cancer cell-line models. CIB2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CIB2 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, CIB2 RNA expression shows 16,637 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, LUAD, and TGCT as cancer lineages where CIB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CIB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CIB2 survival associations across molecular data types. CIB2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CIB2 RNA expression–survival associations across cancer types. High CIB2 expression shows unfavorable associations in SKCM, LGG, LIHC, HNSC and LUAD, but favorable associations in SCLC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CIB2 RNA expression.
This table summarizes CIB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CIB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CIB2 shows lower tumor expression in BRCA and KIRC and higher tumor expression in LUAD, LUSC, LIHC and CHOL. The LUAD box plot shows higher CIB2 RNA expression in tumor versus normal tissue (log2 FC = +1.603, t-test p < 0.001).
This table shows molecular features associated with CIB2 in patient tissues and cancer cell lines. In patient samples, CIB2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CIB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
